Research
<<Back to Main Research Page
Fluoxetine rescues deficient neurogenesis in hippocampus
of the Ts65Dn mouse model for Down syndrome.
• Clark S,
• Schwalbe J,
• Stasko MR,
• Yarowsky PJ,
• Costa AC.
Dept. of Pharmacology and Exp. Therapeutics, University
of Maryland School of Medicine, 655 W. Baltimore Street, Baltimore,
MD 21201-1509, USA.
The Ts65Dn mouse, an adult model of Down syndrome displays
behavioral deficits consistent with a dysfunctional hippocampus,
similar to that seen with DS. In looking for mechanisms underlying
these performance deficits, we have assessed adult neurogenesis
in the dentate gyrus of Ts65Dn. Under untreated conditions,
Ts65Dn mice (2-5 months old) showed markedly fewer BrdU-labeled
cells than euploid animals. Chronic antidepressant treatment
for over 3 weeks with the serotonin selective reuptake inhibitor,
fluoxetine, increased neurogenesis in the Ts65Dn to comparable
levels seen in the euploid by augmenting both proliferation
and survival of BrdU-labeled cells in the subgranular layer
and granule cell layer of the hippocampus, respectively.
PMID: 16624293 [PubMed - in process]
<<Back to Main Research Page
 __________________________________________________________
|
